Trying to shake up the Parkinson's paradigm, AbbVie submits NDA for continuous, 24-hour infusion therapy
AbbVie is approaching the FDA with a new therapy to potentially treat Parkinson’s disease, using prodrugs of two medications commonly used for the condition. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.